Last reviewed · How we verify
mefuparib
mefuparib is a drug. It is currently in unknown development.
Mefuparib works by inhibiting the activity of PARP2, a protein that helps repair damaged DNA.
Mefuparib is a small molecule modality targeting Poly [ADP-ribose] polymerase 2 (PARP2), a protein involved in DNA repair. Its mechanism of action is not classified into a specific drug class. Mefuparib's commercial status and approved indications are currently unknown. Further research is needed to determine its efficacy and safety profile. As a PARP inhibitor, mefuparib may have potential in treating certain types of cancer.
At a glance
| Generic name | mefuparib |
|---|---|
| Target | Poly [ADP-ribose] polymerase 1, Poly [ADP-ribose] polymerase 2 |
| Therapeutic area | Oncology |
| Phase | unknown |
Mechanism of action
Imagine your DNA is a long, fragile thread. PARP2 helps repair breaks in this thread by adding special molecules to fix the damage. Mefuparib blocks this repair process, which can be beneficial in treating cancer cells that rely heavily on PARP2 for survival.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mefuparib CI brief — competitive landscape report
- mefuparib updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about mefuparib
What is mefuparib?
How does mefuparib work?
What development phase is mefuparib in?
What does mefuparib target?
Related
- Target: All drugs targeting Poly [ADP-ribose] polymerase 1, Poly [ADP-ribose] polymerase 2
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing